FDA Learns By Doing In Using REMS Powers; Guidance In “Future”
Executive Summary
FDA decisions on whether to require a risk evaluation and mitigation strategy for a new drug will continue to be made on a case-by-case basis while the agency gains on-the-job experience in interpreting requirements of the FDA Amendments Act
You may also be interested in...
GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine
GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
FDA's risk evaluation and mitigation strategy for fluoroquinolone antibiotics requires manufacturers to survey patients and prescribers to make sure they understand the risks of tendon injury associated with the products